Table 1.
Baseline demographic characteristics of patients with immune-mediated inflammatory disease and control
| RA N=26 820 (%) |
Sjogren’s syndrome N=17 530 (%) |
SLE N=10 014 (%) |
IIM N=1488 (%) |
Systemic sclerosis N=1373 (%) |
Behcet’s disease N=1161 (%) |
Systemic vasculitis N=476 (%) |
Control N=1 000 000 (%) |
|
| Age (y/o) | ||||||||
| Mean | 53.3 (13.9) | 53.5 (13.7) | 39.4 (15.3) | 50.2 (14.3) | 52.0 (13.9) | 38.8 (12.2) | 46.6 (16.5) | 43.1 (16.3) |
| 18–34 | 2574 (9.6) | 1637 (9.3) | 4421 (44.2) | 210 (14.1) | 163 (11.9) | 459 (39.5) | 130 (27.3) | 351 769 (35.2) |
| 35–49 | 7704 (28.7) | 4842 (27.6) | 3247 (32.4) | 488 (32.8) | 382 (27.8) | 473 (40.7) | 137 (28.8) | 314 808 (31.5) |
| 50–64 | 10 810 (40.3) | 7365 (42.0) | 1583 (15.8) | 564 (37.9) | 582 (42.4) | 195 (16.8) | 138 (29.0) | 222 444 (22.2) |
| 65–79 | 4942 (18.4) | 3206 (18.3) | 585 (5.8) | 193 (13.0) | 218 (15.9) | 34* | 62 (13.0) | 86 308 (8.6) |
| >80 | 790 (3.0) | 480 (2.7) | 178 (1.8) | 33 (2.2) | 28 (2.0) | 9 (1.9) | 24 671 (2.5) | |
| Sex | ||||||||
| Female | 20 516 (76.5) | 15 847 (90.4) | 8765 (87.5) | 1002 (67.3) | 985 (71.7) | 658 (56.7) | 264 (55.5) | 501 845 (50.2) |
| Male | 6304 (23.5) | 1683 (9.6) | 1249 (12.5) | 486 (32.7) | 388 (28.3) | 503 (43.3) | 212 (44.5) | 498 155 (49.8) |
| Baseline traditional risk factors | 4101 (15.3) | 3074 (17.5) | 958 (9.6) | 255 (17.14) | 238 (17.33) | 87 (7.5) | 60 (12.61) | 79 138 (7.9) |
| DM | 3062 (11.4) | 1736 (9.9) | 645 (6.4) | 171 (11.5) | 158 (11.5) | 53 (4.6) | 69 (14.5) | 65 047 (6.5) |
| HTN | 5639 (21.0) | 3494 (19.9) | 1445 (14.4) | 320 (21.5) | 327 (23.8) | 94 (8.1) | 118 (24.8) | 109 115 (10.9) |
| Dyslipidaemia | 4101 (15.3) | 3074 (17.5) | 958 (9.6) | 255 (17.1) | 238 (17.3) | 87 (7.5) | 60 (12.6) | 79 138 (7.9) |
| Renal failure | 101 (0.4) | 76 (0.4) | 118 (1.2) | 8 (0.5) | 6 (0.4) | 8* | 17 (3.6) | 1267 (0.1) |
| Atherosclerosis | 171 (0.6) | 109 (0.6) | 53 (0.5) | 9 (0.6) | 34 (2.5) | 16 (3.4) | 2149 (0.2) | |
| Related medications | ||||||||
| Steroids | 21 350 (79.6) | 10 118 (57.7) | 8904 (88.9) | 1445 (97.1) | 992 (72.3) | 977 (84.2) | 424 (89.1) | 177 426 (17.7) |
| Antidiabetics | 2344 (8.7) | 1119 (6.4) | 645 (6.4) | 170 (11.4) | 123 (9.0) | 32 (2.8) | 88 (18.5) | 54 428 (5.4) |
| Diuretics | 4773 (17.8) | 2028 (11.6) | 3172 (31.7) | 531 (35.7) | 422 (30.7) | 76 (6.6) | 192 (40.3) | 45 533 (4.6) |
| Beta-blockers | 4314 (16.1) | 3648 (20.8) | 1982 (19.8) | 328 (22.0) | 262 (19.1) | 162 (14.0) | 148 (31.1) | 83 688 (8.4) |
| CCBs | 4712 (17.6) | 3114 (17.8) | 1921 (19.2) | 356 (23.9) | 519 (37.8) | 90 (7.8) | 167 (35.1) | 89 526 (9.0) |
| Lipid lowing agents | 2365 (8.8) | 1816 (10.4) | 829 (8.3) | 156 (10.5) | 139 (10.1) | 37 (3.2) | 53 (11.1) | 55 615 (5.6) |
| Aspirin | 3318 (12.4) | 2246 (12.8) | 2233 (22.3) | 260 (17.5) | 410 (29.9) | 165 (14.2) | 174 (36.6) | 55 270 (5.5) |
| NSAIDs | 26 372 (98.3) | 15 126 (86.3) | 8625 (86.1) | 1306 (87.8) | 1146 (83.5) | 1023 (88.1) | 398 (83.6) | 607 623 (60.8) |
*Analysis number is combined due to risk of patient identification.
CCB, calcium channel blocker; DM, diabetes mellitus; HTN, hypertension; IIM, idiopathic inflammatory myositis; NSAID, non-steroid anti-inflammatory drug; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.